MeiraGTx’s AAV-GAD gene therapy trial met its safety and tolerability objectives. Credit: MicroOne. A Phase I/II trial (NCT05603312) with MeiraGTx‘s AAV-GAD Parkinson’s disease gene therapy has met ...
AKI can also cause permanent kidney damage. Credit: kan_chana via Shutterstock. Unicycive Therapeutics recently announced positive results from its Phase I trial of UNI-494, [a patented pro-drug of ...